Cargando…

Does Duloxetine Improve Cognitive Function Independently of Its Antidepressant Effect in Patients with Major Depressive Disorder and Subjective Reports of Cognitive Dysfunction?

Introduction. Cognitive deficits are commonly reported by patients with major depressive disorder (MDD). Duloxetine, a dual serotonin/noradrenaline reuptake inhibitor, may improve cognitive deficits in MDD. It is unclear if cognitive improvements occur independently of antidepressant effects with st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greer, Tracy L., Sunderajan, Prabha, Grannemann, Bruce D., Kurian, Benji T., Trivedi, Madhukar H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915915/ https://www.ncbi.nlm.nih.gov/pubmed/24563781 http://dx.doi.org/10.1155/2014/627863

Ejemplares similares

Barriers to implementation of a computerized decision support system for depression: an observational report on lessons learned in "real world" clinical settings
por: Trivedi, Madhukar H, et al.
Publicado: (2009)

Pro-Inflammatory Cytokines as Predictors of Antidepressant Effects of Exercise in Major Depressive Disorder
por: Rethorst, Chad D., et al.
Publicado: (2012)

Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder
por: Jha, Manish K, et al.
Publicado: (2017)

The Combination of Antidepressant Duloxetine with Piracetam in Mice does not Produce Enhancement of Nootropic Activity
por: Kale, Pravin Popatrao, et al.
Publicado: (2014)

The Antidepressant Duloxetine Inhibits Platelet Function and Protects against Thrombosis
por: Lozano, Patricia A., et al.
Publicado: (2022)

Duloxetine in the treatment of major depressive disorder
por: Goldstein, David J
Publicado: (2007)

Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial
por: Cooper, Crystal M., et al.
Publicado: (2019)

Addressing adherence to antidepressant treatment for depression
por: Mayes, Taryn L., et al.
Publicado: (2020)

Functional Connectivity of Brain Structures Correlates with Treatment Outcome in Major Depressive Disorder
por: Kozel, F. Andrew, et al.
Publicado: (2011)

Effectiveness of Duloxetine Monotherapy Compared to Combination Therapy with Other Antidepressants in Patients with Major Depressive Disorder: A Short-Term, Retrospective Study
por: Cheon, Eun-Jin, et al.
Publicado: (2016)

What moderator characteristics are associated with better prognosis for depression?
por: Trivedi, Madhukar H, et al.
Publicado: (2005)

Cognitive dysfunction in young subjects with periodontal disease
por: Hategan, Simona I., et al.
Publicado: (2021)

VitalSign(6): A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression
por: Trivedi, Madhukar H., et al.
Publicado: (2019)

A review of quetiapine in combination with antidepressant therapy in patients with depression
por: Daly, Ella J, et al.
Publicado: (2007)

Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study
por: Petkova, Eva, et al.
Publicado: (2017)

Duloxetine in the treatment of major depressive disorder: an open-label study
por: Hudson, James I, et al.
Publicado: (2007)

Duloxetine-Induced Liver Injury in Patients with Major Depressive Disorder
por: Kang, Seung-Gul, et al.
Publicado: (2011)

Continuation treatment of major depressive disorder: is there a case for duloxetine?
por: Norman, Trevor R, et al.
Publicado: (2010)

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
por: Mahableshwarkar, Atul R., et al.
Publicado: (2015)

An electroencephalographic signature predicts antidepressant response in major depression
por: Wu, Wei, et al.
Publicado: (2020)

Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation
por: Jha, Manish K., et al.
Publicado: (2018)

Effects of the antidepressant medication duloxetine on brain metabolites in persistent depressive disorder: A randomized, controlled trial
por: Bansal, Ravi, et al.
Publicado: (2019)

The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice
por: Ren, Xia, et al.
Publicado: (2022)

Subjective and Objective Cognitive Dysfunction in Schizophrenia – is there a Link?
por: Homayoun, Saffron, et al.
Publicado: (2011)

Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder
por: Zuckerman, Hannah, et al.
Publicado: (2018)

Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder
por: Lee, Jeong-Ok, et al.
Publicado: (2018)

Independent association between subjective cognitive decline and frailty in the elderly
por: Hsieh, Tsung-Jen, et al.
Publicado: (2018)

Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder
por: Park, Young-Min, et al.
Publicado: (2010)

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
por: Ye, Wenyu, et al.
Publicado: (2011)

Cognitive processing and body balance in elderly subjects with vestibular dysfunction
por: dos Santos Caixeta, Giovanna Cristina, et al.
Publicado: (2015)

Duloxetine hydrochloride
por: Bhadbhade, Mohan, et al.
Publicado: (2009)

Duloxetine induced hyponatremia
por: Kulkarni, M.
Publicado: (2015)

Dysfunction of basal ganglia functional connectivity associated with subjective and cognitive fatigue in multiple sclerosis
por: Langley, Christelle, et al.
Publicado: (2023)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman, Robert M, et al.
Publicado: (2011)

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006)

Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder
por: Muscatello, Maria Rosaria Anna, et al.
Publicado: (2019)

Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine – a quantitative EEG study in rats
por: Leiser, S C, et al.
Publicado: (2014)

Independent replication of advanced brain age in mild cognitive impairment and dementia: detection of future cognitive dysfunction
por: Karim, Helmet T., et al.
Publicado: (2022)

Discrepancy between objective and subjective cognition in adults with major depressive disorder
por: Srisurapanont, Manit, et al.
Publicado: (2017)

A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction
por: Keefe, Richard S E, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_643l13fa74bva8orohpnmu76ua